[go: up one dir, main page]

HK1198811A1 - 包含瑞巴匹特和眼淚保持劑的用於治療前眼疾病的藥物 - Google Patents

包含瑞巴匹特和眼淚保持劑的用於治療前眼疾病的藥物

Info

Publication number
HK1198811A1
HK1198811A1 HK14112267.5A HK14112267A HK1198811A1 HK 1198811 A1 HK1198811 A1 HK 1198811A1 HK 14112267 A HK14112267 A HK 14112267A HK 1198811 A1 HK1198811 A1 HK 1198811A1
Authority
HK
Hong Kong
Prior art keywords
rebamipide
drug
eye diseases
retention agent
anterior eye
Prior art date
Application number
HK14112267.5A
Other languages
English (en)
Chinese (zh)
Inventor
Yasuhiro Takeji
Hideo Nakashima
Hiroki Urashima
Hisashi Shinohara
Yuki Hirata
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47215697&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1198811(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of HK1198811A1 publication Critical patent/HK1198811A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47042-Quinolinones, e.g. carbostyril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728Hyaluronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/30Zinc; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
HK14112267.5A 2011-11-01 2014-12-05 包含瑞巴匹特和眼淚保持劑的用於治療前眼疾病的藥物 HK1198811A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011240177 2011-11-01
PCT/JP2012/078769 WO2013065866A1 (en) 2011-11-01 2012-10-31 A medicament for treating anterior eye disease comprising rebamipide and a tear-retaining agent

Publications (1)

Publication Number Publication Date
HK1198811A1 true HK1198811A1 (zh) 2015-06-12

Family

ID=47215697

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14112267.5A HK1198811A1 (zh) 2011-11-01 2014-12-05 包含瑞巴匹特和眼淚保持劑的用於治療前眼疾病的藥物

Country Status (19)

Country Link
US (1) US20140294991A1 (xx)
EP (1) EP2773350A1 (xx)
JP (1) JP6060168B2 (xx)
KR (1) KR101951511B1 (xx)
CN (1) CN103945846A (xx)
AR (1) AR088585A1 (xx)
AU (1) AU2012333448A1 (xx)
BR (1) BR112014010376A2 (xx)
CA (1) CA2851095A1 (xx)
CO (1) CO6960545A2 (xx)
EA (1) EA201490721A1 (xx)
HK (1) HK1198811A1 (xx)
IL (1) IL231922A0 (xx)
IN (1) IN2014CN03123A (xx)
MX (1) MX2014005209A (xx)
PH (1) PH12014500967A1 (xx)
SG (1) SG11201401502TA (xx)
TW (1) TW201322982A (xx)
WO (1) WO2013065866A1 (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6081173B2 (ja) * 2011-12-12 2017-02-15 ロート製薬株式会社 眼科用水性組成物
TW201417814A (zh) * 2012-09-28 2014-05-16 Otsuka Pharma Co Ltd 包括瑞巴派特之醫藥組成物
JP6267003B2 (ja) * 2014-02-27 2018-01-24 参天製薬株式会社 ジクアホソルまたはその塩およびレバミピドまたはその塩を組み合わせたことを特徴とする涙液分泌促進剤
JP2017052723A (ja) * 2015-09-10 2017-03-16 株式会社Lttバイオファーマ ドライアイ改善剤
KR20170039347A (ko) * 2015-10-01 2017-04-11 삼진제약주식회사 레바미피드를 함유하는 신규한 점안 조성물 및 이의 제조방법
GB201618175D0 (en) * 2016-10-27 2016-12-14 Warneford Healthcare Ltd Pharmaceutical compositions
KR101840256B1 (ko) * 2017-09-21 2018-03-21 대우제약 주식회사 레바미피드를 함유하는 새로운 안구건조증 치료용 점안 조성물 및 이의 가용화 및 안정화 방법
KR101923519B1 (ko) 2018-06-26 2019-02-27 대우제약 주식회사 레바미피드를 함유하는 안구 건조증 치료용 수용성 다회용 점안제 조성물 및 이의 가용화 및 안정화 방법
KR20200019451A (ko) 2018-08-14 2020-02-24 대우제약 주식회사 레바미피드를 함유하는 안구 건조증 치료용 수용성 다회용 점안제 조성물 및 이의 가용화 및 안정화 방법
WO2020138135A1 (ja) 2018-12-26 2020-07-02 ライオン株式会社 眼科用組成物
US20240390416A1 (en) * 2021-09-30 2024-11-28 Rohto Pharmaceutical Co., Ltd. Ophthalmological composition

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6084225A (ja) * 1983-10-17 1985-05-13 Hiroko Shimizu 点眼剤
JPH0723317B2 (ja) * 1988-03-17 1995-03-15 生化学工業株式会社 角膜上皮層障害症治療剤
JP3093661B2 (ja) * 1995-10-12 2000-10-03 大塚製薬株式会社 眼疾患治療剤
AR004214A1 (es) * 1995-10-12 1998-11-04 Otsuka Pharma Co Ltd Una preparación de gotas oftálmicas para la cura de enfermedades oftálmicas
TWI363626B (en) * 2004-11-15 2012-05-11 Otsuka Pharma Co Ltd Aqueous ophthalmic suspension of crystalline rebamipide
US8388995B1 (en) * 2006-02-03 2013-03-05 Auburn University Controlled and extended delivery of hyaluronic acid and comfort molecules via a contact lens platform
TWI415629B (zh) 2006-10-26 2013-11-21 Otsuka Pharma Co Ltd 含有瑞巴匹特之水性醫藥懸浮物及其製造方法
EA017752B1 (ru) * 2006-12-11 2013-02-28 Сигма-Тау Индустрие Фармасьютике Риуните С.П.А. Применение l-карнитина для получения лекарственного средства в форме глазных капель для лечения отека роговицы
WO2008074853A1 (en) * 2006-12-21 2008-06-26 Novartis Ag Ophthalmic rebamipide solution
BRPI0915427A2 (pt) * 2008-06-19 2015-11-03 Otsuka Pharma Co Ltd composição farmacêutica
US20120003296A1 (en) * 2010-07-01 2012-01-05 Shantha Totada R New methods of treating dry eye syndrome
US20110021974A1 (en) * 2010-10-05 2011-01-27 Shantha Totada R Retinitis pigmentosa treatment and prophalaxis
US20110052678A1 (en) * 2010-11-05 2011-03-03 Shantha Totada R Method for treating age related macular degeneration

Also Published As

Publication number Publication date
KR20140087030A (ko) 2014-07-08
JP2014532641A (ja) 2014-12-08
EA201490721A1 (ru) 2014-08-29
MX2014005209A (es) 2014-05-28
WO2013065866A1 (en) 2013-05-10
CN103945846A (zh) 2014-07-23
CA2851095A1 (en) 2013-05-10
IN2014CN03123A (xx) 2015-07-03
KR101951511B1 (ko) 2019-02-22
AR088585A1 (es) 2014-06-18
CO6960545A2 (es) 2014-05-30
JP6060168B2 (ja) 2017-01-11
TW201322982A (zh) 2013-06-16
SG11201401502TA (en) 2014-09-26
IL231922A0 (en) 2014-05-28
AU2012333448A1 (en) 2014-05-22
PH12014500967A1 (en) 2019-10-07
EP2773350A1 (en) 2014-09-10
BR112014010376A2 (pt) 2017-04-25
US20140294991A1 (en) 2014-10-02

Similar Documents

Publication Publication Date Title
HK1198811A1 (zh) 包含瑞巴匹特和眼淚保持劑的用於治療前眼疾病的藥物
HK1246646A1 (zh) 用於治療糖尿病性視網膜病及其他眼科疾病的方法
HK1205461A1 (en) Compositions and methods for ocular delivery of a therapeutic agent
HUE045821T2 (hu) Vegyületek célzott gyógyszerszállításra és a siRNA-aktivitás fokozására
HK1201196A1 (en) Treatment of ocular disease
HK1219888A1 (zh) 用於無創眼部藥物遞送的包含聚合物微粒的溫敏性水凝膠
HUE046963T2 (hu) Készítmények és kezelés szembetegségekhez és rendellenességekhez
SG11201502274XA (en) A device for a medical treatment of a sclera
IL230957A0 (en) Pharmacy methods and preparations for the treatment of an eye disease in a patient
HK1211249A1 (en) Device and methods for targeted tissue drug delivery
IL227412A (en) Administration of cross-materials to corne by iontophoresis for the treatment of keratoconus and ophthalmic preparations for this purpose
CL2013002134A1 (es) Composicion farmaceutica oftalmica de administracion topica que comprende un androgeno; y metodo para tratar una afeccion ocular resultante de una deficiencia de androgeno.
IL232999B (en) A preparation for the treatment of an eye disease associated with an amino acid when the preparation contains a nuclease and an ophthalmic excipient
HRP20130830T1 (xx) Emulzija tipa vode u ulju za lijeäśenje oäśnih bolesti
BR112013024169A2 (pt) método para o tratamento e prevenção da doença de parkinson
DK2747763T3 (da) (bacterio-)chlorofyllfotosensibilisatorer til behandling af øjensygdomme og -lidelser
PL2701645T3 (pl) Urządzenie do leczenia i/lub zapobiegania chorobom rogówki
IL230960A0 (en) A device for the treatment of eye disease
EP2906295A4 (en) METHODS OF TREATING OCULAR DISEASES
HK1186660A1 (en) A water-in-oil type emulsion for treating a disease of the eye
EP2558104A4 (en) METHOD AND OPHTHALMIC COMPOSITION FOR TREATING RETINAL DISEASE
IL235874A0 (en) Treatment of ocular inflammatory diseases by laquinimod
IL230959B (en) A device for the treatment of eye disease
BR112013009701A2 (pt) regimes de dosagem para o tratamento de doença vascular ocular
PT2603238E (pt) Métodos e composições farmacêuticas para o tratamento de uma doença ocular num indíviduo